Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 181

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1
Chunk 181
---
, 2025, the second and third patients, respectively, were treated with the Aethlon Hemopurifier at GenesisCare North
Shore in Sydney, Australia. Each patient underwent a single 4-hour treatment session and tolerated the procedure without complications.
Follow-up visits will include safety assessments, extracellular vesicle (EV) and T cell measurements, as well as imaging to evaluate clinical
response.

RSU Grants

In April
2025, our Board of Directors approved, pursuant to the terms of the Director Compensation Policy, the grant of the annual RSUs under the
Director Compensation Policy to each of the four non-employee directors of the Company then serving on the Board of Directors. The Director
Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning of each fiscal year for current non-employee
directors then serving on the Board of Directors, and for a grant of stock options or $75,000 worth of RSUs for a newly elected non-employee
director, with each RSU priced at the average for the closing prices for the five days preceding and including the date of grant, or $2.80
per share for the RSUs granted in April 2025. As a result, in April 2025 the four eligible directors were each granted an RSU in the amount
of 17,858 shares under the Company’s 2020 Equity Incentive Plan, or the 2020 Plan. The RSUs are subject to vesting in
four equal installments, with 25% of the restricted stock units vesting on each of June 30, 2025, September 30, 2025, December 31, 2025,
and March 31, 2026, subject in each case to the director’s Continuous Service (as defined in the 2020 Plan), through such dates.
Vesting will terminate upon the director’s termination of Continuous Service prior to any vesting date.

 F-26